1 Arzneimittelinformation der Swissmedic Ciproxin®
(
www.swissmedicinfo.ch)
2 Weiler S, Corti N. Antibiotic therapy: impact and resistance. Med Klin Intensivmed Notfmed. 2014;109:167–74.
3 Bolon B. Mini-Review: Toxic Tendinopathy. Toxicol Pathol. 2017;45:834–7.
4 Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36:1404–10.
5 Micromedex® 2.0, (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA.
http://www.micromedexsolutions.com/ (Zugriff August 8, 2017).
6 Wise BL, Peloquin C, Choi H, Lane NE, Zhang Y. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med. 2012;125:1228.e23–1228.e28.
7 van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ. 2002;324:1306–7.
8 Maurin N. Fluoroquinolone-induced Achilles tendon rupture. Dtsch Med Wochenschr. 2008;133:241–4.
9 Muzi F, Gravante G, Tati E, Tati G. Fluoroquinolones-induced tendinitis and tendon rupture in kidney transplant recipients: 2 cases and a review of the literature. Transplant Proc. 2007;39:1673–5.
10 Food and Drug Administration. Drug Safety Communications.
http://www.fda.gov/downloads/Drugs/DrugSafety/UCM500591.pdf. Publiziert Mai 12, 2016. (Zugriff März 13, 2017).
11 Arzneimittelinformation der Swissmedic Sortis® (
www.swissmedicinfo.ch)
12 Arzneimittelinformation der Swissmedic Prednison Galepharm (
www.swissmedicinfo.ch)
13 Golomb BA, Koslik HJ, Redd AJ. Fluoroquinolone-induced serious, persistent, multisymptom adverse effects. BMJ Case Rep. 2015;2015. pii: bcr2015209821.
14 Lowes DA, Wallace C, Murphy MP, Webster NR, Galley HF. The mitochondria targeted antioxidant MitoQ protects against fluoroquinolone-induced oxidative stress and mitochondrial membrane damage in human Achilles tendon cells. Free Radic Res. 2009;43:323–8.
15 Tsai WC, Hsu CC, Chen CP, Chang HN, Wong AM, Lin MS, Pang JH. Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen. J Orthop Res. 2011;29:67–73.